INS and Hypoglycemia: Considering the long duration of action of this type of novel insulin construct and that it most likely functions as a basal insulin, and as a precautionary measure to minimize the risk of hypoglycemia, we used an initial starting dose intended to approximate 0.3 U/kg/day (or 2.1 U/kg/week) with the goal of slowly increasing the dose throughout the 8 weeks of treatment, as necessary.